Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Christina-Nefeli Kontandreopoulou, BSc, Panagiotis T Diamantopoulos, MD PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Andreas Giannopoulos, BSc, MSc, Katerina Zoi, PhD, Maria Dimou, MD PhD, Elena E. Solomou, MD, Panayiotis Panayiotidis, MD, Georgios Kyriakakis, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Chatzidavid, Nora-Athina Viniou, MD PhD

Blood (2019) 134 (Supplement_1): 1721.

https://doi.org/10.1182/blood-2019-126426

Published: 2019

Journal Articles

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics

Nefeli Giannakopoulou, Marianna Politou, MD, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitris Korakakis, Maria Efstathopoulou, Theodora Kassi, Christina-Nefeli Kontandreopoulou, Katerina Zoi, PhD, Andreas Giannopoulos, BSc, MSc, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Nora-Athina Viniou, MD

Blood (2018) 132 (Supplement 1): 4304.

https://doi.org/10.1182/blood-2018-99-116660

Published: 2018

Journal Articles

Concurrent or Sequential BCR-ABL Translocation and Calr gene or JAK2 V617F Mutation

Maria Pagoni, Maria Garofalaki, Irene Tziotziou, Evaggelia Nikolou, Stamatis Karakatsanis, Ioannis Tsonis, Katerina Zoi, Ioannis Baltathakis, Dimitrios Karakasis, Nikolaos Harhalakis

Blood (2014) 124 (21): 1844.

https://doi.org/10.1182/blood.V124.21.1844.1844

Published: 2014

Journal Articles

Latent Myeloproliferative Neoplasm May Underlie Retinal Vein Occlusion In Older Patients

Katerina Zoi, PhD, Christine Zoi, Andreas Giannopoulos, MSc, Argyri Gialeraki, PhD, Kassiani Giannaki, MD, PhD, Niki Rougkala, Panagiotis Theodosiadis, MD, John Vergados, MD, Dimitris Loukopoulos, Nicholas C.P. Cross, PhD, FRCPath, Marianna Politou

Blood (2013) 122 (21): 5242.

https://doi.org/10.1182/blood.V122.21.5242.5242

Published: 2013

Journal Articles

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Blood (2013) 122 (21): 104.

https://doi.org/10.1182/blood.V122.21.104.104

Published: 2013

Journal Articles

Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis

Blood (2012) 120 (21): 431.

https://doi.org/10.1182/blood.V120.21.431.431

Published: 2012

Journal Articles

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Joannah Score, Claire Hidalgo-Curtis, Amy V. Jones, Nils Winkelmann, Alison Skinner, Daniel Ward, Katerina Zoi, Thomas Ernst, Frank Stegelmann, Konstanze Döhner, Andrew Chase, Nicholas C. P. Cross

Blood (2012) 119 (5): 1208–1213.

https://doi.org/10.1182/blood-2011-07-367243

Published: 2012

Includes: Supplemental data

Journal Articles

Inactivation of Polycomb Repressive Complex 2 Components in Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms

Nicholas C.P. Cross, PhD, FRCPath, Joannah Score, PhD, Claire Hidalgo-Curtis, PhD, Amy V Jones, PhD, Nils Winkelmann, MD, Alison Skinner, BSc, Daniel Ward, MSc, Katerina Zoi, MD, PhD, Thomas Ernst, MD, Frank Stegelmann, MD, Konstanze Dohner, MD, PhD, Andrew J Chase, PhD

Blood (2011) 118 (21): 617.

https://doi.org/10.1182/blood.V118.21.617.617

Published: 2011

Journal Articles

Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis

Paola Guglielmelli, MD, PhD, Flavia Biamonte, BiSc, Johannah Score, Claire Hidalgo-Curtis, PhD, Francisco Cervantes, MD, PhD, Margherita Maffioli, MD, Tiziana Fanelli, BiSci, Thomas Ernst, MD, Nils Winkelman, MD, Amy V Jones, PhD, Katerina Zoi, MD, PhD, Andreas Reiter, MD, Andrew Duncombe, MD, Laura Villani, Biol Sci, Chiara Paoli, BiSci, Alberto Bosi, MD, Giovanni Barosi, MD, Nicholas C.P. Cross, PhD, Alessandro M. Vannucchi, MD

Blood (2011) 118 (21): 2811.

https://doi.org/10.1182/blood.V118.21.2811.2811

Published: 2011

Journal Articles

EZH2 mutational status predicts poor survival in myelofibrosis

Paola Guglielmelli, Flavia Biamonte, Joannah Score, Claire Hidalgo-Curtis, Francisco Cervantes, Margherita Maffioli, Tiziana Fanelli, Thomas Ernst, Nils Winkelman, Amy V. Jones, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Laura Villani, Alberto Bosi, Giovanni Barosi, Nicholas C. P. Cross, Alessandro M. Vannucchi

Blood (2011) 118 (19): 5227–5234.

https://doi.org/10.1182/blood-2011-06-363424

Published: 2011

Includes: Supplemental data

Journal Articles

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Blood (2010) 116 (22): e111–e117.

https://doi.org/10.1182/blood-2010-06-291641

Published: 2010

Includes: Supplemental data

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

Journal Articles

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

Blood (2010) 116 (21): 894.

https://doi.org/10.1182/blood.V116.21.894.894

Published: 2010

Journal Articles

The JAK2 46/1 haplotype predisposes to MPL -mutated myeloproliferative neoplasms

Amy V. Jones, Peter J. Campbell, Philip A. Beer, Susanne Schnittger, Alessandro M. Vannucchi, Katerina Zoi, Melanie J. Percy, Mary Frances McMullin, Linda M. Scott, William Tapper, Richard T. Silver, David Oscier, Claire N. Harrison, Harald Grallert, Aliaksei Kisialiou, Paul Strike, Andrew J. Chase, Anthony R. Green, Nicholas C. P. Cross

Blood (2010) 115 (22): 4517–4523.

https://doi.org/10.1182/blood-2009-08-236448

Published: 2010

Includes: Supplemental data

Journal Articles

Frequent Inactivating Mutations of TET2 and CBL Are Associated with Acquired Uniparental Disomy in Atypical Chronic Myeloid Leukemia and Related Disorders.

Thomas Ernst, MD, Andrew Chase, PhD, Claire Hidalgo-Curtis, PhD, Katerina Zoi, PhD, Christine Zoi, MD, Andreas Hochhaus, MD, Andreas Reiter, MD, William Vainchenker, MD, PhD, Francis Grand, PhD, Nicholas C.P. Cross, PhD

Blood (2009) 114 (22): 3258.

https://doi.org/10.1182/blood.V114.22.3258.3258

Published: 2009

Journal Articles

The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations.

Nicholas C.P. Cross, PhD, FRCPath, Peter Campbell, MD, PhD, Philip A Beer, BM, MRCP, MRCPath, Susanne Schnittger, PhD, Alessandro M. Vannucchi, MD, Katerina Zoi, PhD, Melanie Percy, PhD, FRCPath, Mary Frances McMullin, Linda Scott, BSc, PhD, Richard T. Silver, MD, David Oscier, MD, Claire Harrison, MD, Anthony R. Green, FRCP, FRCPath, FMed, Sci, Andrew Chase, PhD

Blood (2009) 114 (22): 433.

https://doi.org/10.1182/blood.V114.22.433.433

Published: 2009

Journal Articles

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

Francis H. Grand, Claire E. Hidalgo-Curtis, Thomas Ernst, Katerina Zoi, Christine Zoi, Carolann McGuire, Sebastian Kreil, Amy Jones, Joannah Score, Georgia Metzgeroth, David Oscier, Andrew Hall, Christian Brandts, Hubert Serve, Andreas Reiter, Andrew J. Chase, Nicholas C. P. Cross

Blood (2009) 113 (24): 6182–6192.

https://doi.org/10.1182/blood-2008-12-194548

Published: 2009

Journal Articles

Frequent CBL Mutations Associated with 11q Acquired Uniparental Disomy in Myeloproliferative Neoplasms

Francis Grand, PhD, Claire Hidalgo-Curtis, BSc, Thomas Ernst, MD, Katerina Zoi, PhD, Christine Zoi, MD, Carolann McGuire, PhD, Sebastian Kreil, MD, Georgia Metzgeroth, MD, David Oscier, MD, Andrew Hall, PhD, Christian Brandts, MD, Hubert Serve, Andreas Reiter, MD, Andrew Chase, PhD, Nicholas C.P. Cross, PhD

Blood (2008) 112 (11): 174.

https://doi.org/10.1182/blood.V112.11.174.174

Published: 2008

Journal Articles

No Evidence for Increased Prevalence of JAK2 V617F in Women with a History of Recurrent Miscarriage

Issa J. Dahabreh, Amy V. Jones, Michael Voulgarelis, Christina Alafakis-Tzannatos, Stavroula Giannouli, Marighoula Varla-Leftherioti, Theodora Keramitsoglou, Christine Zoi, Dimitris Loukopoulos, Stelios Fotiou, Nicholas C.P. Cross, PhD, Katerina Zoi, PhD

Blood (2008) 112 (11): 5235.

https://doi.org/10.1182/blood.V112.11.5235.5235

Published: 2008

Journal Articles

Mutations in the Exon 12 of the JAK2 Gene Appeared To Be a Rare Event Essentially Clustered in V617F JAK2 Negative PV Patients.

Eirini Kouroupi, MD, Nathalie Parquet, MD, Christine Zoi, MD, Jean-Jacques Kiladjian, MD, Vassiliki Grigoraki, MD, Katerina Zoi, PhD, Linda Scott, PhD, Christine Dosquet, MD, Pierre Fenaux, MD, PhD, Dimitris Loukopoulos, MD, PhD, Christine Chomienne, MD, PhD, Bruno Cassinat, PharmD

Blood (2007) 110 (11): 2534.

https://doi.org/10.1182/blood.V110.11.2534.2534

Published: 2007

NARROW

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics

Concurrent or Sequential BCR-ABL Translocation and Calr gene or JAK2 V617F Mutation

Latent Myeloproliferative Neoplasm May Underlie Retinal Vein Occlusion In Older Patients

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Inactivation of Polycomb Repressive Complex 2 Components in Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms

Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis

EZH2 mutational status predicts poor survival in myelofibrosis

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

The JAK2 46/1 haplotype predisposes to MPL -mutated myeloproliferative neoplasms

Frequent Inactivating Mutations of TET2 and CBL Are Associated with Acquired Uniparental Disomy in Atypical Chronic Myeloid Leukemia and Related Disorders.

The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations.

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

Frequent CBL Mutations Associated with 11q Acquired Uniparental Disomy in Myeloproliferative Neoplasms

No Evidence for Increased Prevalence of JAK2 V617F in Women with a History of Recurrent Miscarriage

Mutations in the Exon 12 of the JAK2 Gene Appeared To Be a Rare Event Essentially Clustered in V617F JAK2 Negative PV Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only